Virologic Failure of Protease Inhibitor-Based Second-Line Antiretroviral Therapy without Resistance in a Large HIV Treatment Program in South Africa

doi:10.1371/journal.pone.0032144

PLoS One. 2012; 7(3): e32144.

Published online 2012 March 13. doi: 10.1371/journal.pone.0032144

PMCID: PMC3302781

Copyright Levison et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Virologic Failure of Protease Inhibitor-Based Second-Line Antiretroviral Therapy without Resistance in a Large HIV Treatment Program in South Africa

Julie H. Levison,^1,^2,⁴^* Catherine Orrell,^#³ Sébastien Gallien,^#^4,⁶ Daniel R. Kuritzkes,^4,⁶ Naishin Fu,¹ Elena Losina,^1,^5,⁶ Kenneth A. Freedberg,^1,^2,^5,⁶ and Robin Wood³

¹Division of General Medicine Massachusetts General Hospital, Boston, Massachusetts, United States of America

²Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America

³Department of Medicine, Desmond Tutu HIV Center, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa

⁴Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, United States of America

⁵Departments of Biostatistics and Epidemiology, Boston University School of Public Health, Boston, Massachusetts, United States of America

⁶Harvard University Center for AIDS Research, Harvard University, Boston, Massachusetts, United States of America

Matthew P. Fox, Editor

Boston University, United States of America

^#Contributed equally.

* E-mail: jlevison/at/partners.org

Conceived and designed the experiments: JHL CO SG DRK KAF RW. Performed the experiments: JHL SG. Analyzed the data: JHL CO SG DRK EL KAF RW. Contributed reagents/materials/analysis tools: CO RW SG DRK . Wrote the paper: JHL. Critical editing of the Manuscript: JHL CO SG DRK EL KAF RW NF.

Received July 8, 2011; Accepted January 20, 2012.

Abstract

Background

We investigated the prevalence of wild-type virus (no major drug resistance) and drug resistance mutations at second-line antiretroviral treatment (ART) failure in a large HIV treatment program in South Africa.

Methodology/ Principal Findings

HIV-infected patients ≥15 years of age who had failed protease inhibitor (PI)-based second-line ART (2 consecutive HIV RNA tests >1000 copies/ml on lopinavir/ritonavir, didanosine, and zidovudine) were identified retrospectively. Patients with virologic failure were continued on second-line ART. Genotypic testing for drug resistance was performed on frozen plasma samples obtained closest to and after the date of laboratory confirmed second-line ART failure. Of 322 HIV-infected patients on second-line ART, 43 were adults with confirmed virologic failure, and 33 had available plasma for viral sequencing. HIV-1 RNA subtype C predominated (n

32, 97%). Mean duration on ART (SD) prior to initiation of second-line ART was 23 (17) months, and time from second-line ART initiation to failure was 10 (9) months. Plasma samples were obtained 7(9) months from confirmed failure. At second-line failure, 22 patients (67%) had wild-type virus. There was no major resistance to PIs found. Eleven of 33 patients had a second plasma sample taken 8 (5.5) months after the first. Median HIV-1 RNA and the genotypic resistance profile were unchanged.

Conclusions/ Significance

Most patients who failed second-line ART had wild-type virus. We did not observe evolution of resistance despite continuation of PI-based ART after failure. Interventions that successfully improve adherence could allow patients to continue to benefit from second-line ART therapy even after initial failure.

Introduction

South Africa has the largest government-sponsored antiretroviral treatment (ART) program in the world [1]. Given the scarcity of salvage ART regimens in South Africa and other resource-limited settings and the high cost of second-line ART [2], rational use of second-line ART is critical.

International guidelines endorse boosted protease inhibitor (PI)-based combination ART as an efficacious strategy after failure of NNTRI-based first line ART [3]. Most adults are PI-naive at second-line ART initiation, PI resistance at failure of first-line NNRTI-based ART is uncommon [4], and PI-based second-line ART is highly potent [5]. Nevertheless, up to 40% of HIV-1 infected adults in South Africa develop confirmed virologic failure on second-line ART [6], [7], [8], [9].

In resource-limited settings such as South Africa, many unanswered questions remain about the contribution of drug resistance to second-line ART failure. They include uncertainties about the susceptibility of HIV-1 subtype C, which accounts for nearly half of global infections and the majority in South Africa [4], [10], [11]; effectiveness of ART delivery in public health clinics; and medication non-adherence.

Here, we investigated the extent to which drug resistance mutations contribute to second-line ART failure in a large community-based ART program in South Africa.

Methods

Ethics Statement

All study participants provided written informed consent. For participants age ≤18 years, an accompanying parent or guardian also provided written consent. Study procedures were approved by the University of Cape Town (Cape Town, South Africa) and the Partners HealthCare Human Research Committee (Boston, Massachusetts, USA).

Study setting and population

The Gugulethu Clinic is an HIV referral center for a peri-urban township of Cape Town, South Africa. The clinic provides HIV-related care for more than 6,000 patients and serves an impoverished population of more than 300,000 individuals where the ante-natal HIV seroprevalence was 29% in 2006 [9], [12], [13]. Clinic demographic and clinical characteristics are consistent with other large ART roll-out programs in South Africa [10], [14]. Clinical data are prospectively maintained in an electronic database at the Desmond Tutu HIV Center. First-line ART consists of stavudine in the majority of cases, or zidovudine, with lamivudine and either efavirenz or nevirapine. Second-line ART includes zidovudine, didanosine, and lopinavir/ritonavir as per national protocol [15]. Consistent with national ART guidelines, patients were eligible to switch to second-line ART if they have persistent observed HIV viremia (HIV RNA>1000 copies/ml) at 2 consecutive occasions 3 months apart, despite an adherence intervention [15]. Patients with virologic failure are generally continued on second-line ART.

Study Design

Data from HIV-infected patients ≥15 years of age who had failed second-line therapy (2 consecutive HIV-1 RNA tests >1000 copies/ml) by October 1, 2009, were analyzed retrospectively using a cross sectional design. A single local laboratory performed HIV-1 RNA assays by branch DNA hybridization techniques (HIV-1 RNA 3.0 assay®; Bayer Healthcare, Leverkusen, Germany) and CD4-count by flow cytometry (FACS Count™, Becton, Dickinson and Company, Franklin Lakes, NJ, USA). Genotypic testing for drug resistance was performed on frozen plasma samples obtained closest to, and on or after the date of laboratory confirmed second-line ART failure. We used International AIDS Society-USA criteria to define drug resistance mutations [16]. Some patients who failed second-line ART had genotypic drug resistance results available from first-line ART failure [4].

Viral sequencing from plasma

Viral RNA was extracted (QIAamp viral RNA minikit, QIAGEN Inc) from 140 µl of each plasma sample and HIV-1 protease (PR codons 1–99, HXB2 nucleotides 2254–2549) and reverse transcriptase (RT codons 1–343, HXB2 nucleotides 2550–3577) were amplified by a 1-step reverse transcription–polymerase chain reaction (PCR), followed by a nested-PCR using gene-specific primers, as described [17].

Population (“bulk”) sequencing was performed on resulting amplicons with the Taq Dye Deoxy Terminator Kit (Applied Biosystems, Inc.) and resolved on an ABI 3730 automated DNA sequencer. Sequence processing was done using the Sequencher program (Genecodes). Sequences were aligned to the HIV-1 subtype B reference strain HXB2 (GenBank accession no. K03455).

Each sample was amplified in duplicate. A phylogenetic tree, using the PhyML program and including all the sequences generated as well as HXB2 and NL4-3 corresponding sequences, was used to confirm specimen identity and the absence of cross-contamination as an adjunct to the PCR negative control.

Statistical Analysis

Mean values were reported with standard deviations (SD). Demographic and laboratory characteristics were examined for association with drug-resistant virus at second-line ART failure. We used Fisher's exact test to compare the association of categorical variables, age dichotomized at the mean (≤35 or >35 years), and HIV-1 RNA (≤10,000 copies/ml and >10,000 copies/ml) with the outcome. Statistical tests were two-sided with a significance level of 0.05. All statistical analyses were performed using SAS 9.1 software (Cary, North Carolina).

Results

Of 322 HIV-infected patients receiving second-line ART, 43 were adults (≥15 years) with confirmed virologic failure (Figure 1). Of these, 33 had plasma available for viral sequencing. No differences in age (p

0.19), sex (p

0.66), or viral load (p

0.83) at second-line ART failure were found when comparing the 10 adults without plasma available for sequencing to the analyzed cohort. Of the 33 adults, mean (SD) age was 34 (8) years; 28 (85%) were female. HIV-1 RNA subtype C predominated (n

32, 97%). Thirty-two of 33 individuals had available first-line treatment history. The majority (n

30; 94%) received a stavudine-lamivudine based regimen; the remainder received zidovudine-lamivudine. Similarly, most patients received efavirenz as the NNRTI component (n

24; 75%), and the rest received nevirapine. Mean (SD) duration on ART prior to initiation of second-line treatment was 23 (17) months. The median time between confirmatory HIV viral loads on second-line ART was 7 months. Mean time from second-line ART initiation to failure was 10 (9) months. Plasma samples available for analysis were obtained a mean of 7 (9) months from confirmed second-line failure.

Figure 1

Study flow diagram.

At second-line ART initiation, median CD4 count was 210/µl [IQR 108–310/µl] and median HIV-1 RNA was 4.1 log₁₀ copies/ml [IQR 3.5–4.7 log₁₀ copies/ml], which increased to a median HIV-1 RNA of 4.6 log₁₀ copies/ml [IQR 4.1–5.1 log₁₀ copies/ml] at second-line failure.

At the first sample collection at second-line failure, virus from 22 patients (67%) was wild-type or lacked major drug resistance mutations (Table 1). Among samples with resistance mutations, NRTI resistance mutations were rare. Samples from 11 patients (33%) had major NNRTI resistance; of these, 9 patients had virus with only major NNRTI resistance and 2 patients had virus with both NRTI and NNRTI resistance. The most common NNRTI mutation was K103N (n

5, 15%) found alone in 4 patients and with Y181C in another patient. Both Y181C (n

3, 9%) and G190A (n

3, 9%) were present with other resistance mutations. P225H (n

1, 3%) occurred without other NNRTI resistance mutations. Resistance mutations that may reduce susceptibility to etravirine were assessed and were infrequent (Table 1).

Table 1

Distribution of genotypic drug resistance mutations for patients with virologic failure on second-line ART in a large ART roll-out program in South Africa.

Mutations classified as “minor” PI resistance mutations by the IAS-USA were detected in 30 of 33 (91%) individuals; no major PI resistance mutations were found. The most frequent minor PI resistance mutations included K20R (n

9, 27%); M36I (n

30, 91%), L63P (n

14, 42%), H69K (n

32, 97%), and I93L (n

31, 94%). Less commonly found mutations included L10FV (n

2, 6%) D60E (n

5, 15%), and I62V (n

3, 9%).

Ten individuals had HIV-1 genotypes from the time of first-line ART failure available. The same minor PI resistance mutations present at second-line ART failure were also present at first-line ART failure, prior to PI exposure. Virus from 8 individuals had M184V at first-line ART failure; in 7 individuals this mutation was undetectable at second-line failure. All samples in which the M184V mutation was detected at first-line failure also carried major NNRTI resistance mutations. Of the 9 individuals with virus containing major NNRTI resistance mutations at first-line failure, 6 retained virus with detectable major NNRTI resistance mutations at second-line failure. Samples from 2 individuals had thymidine analog mutations (TAMs) at first-line ART failure, which were not detected at second-line ART failure.

Eleven of 33 patients had a second sample for resistance testing taken 8 (5.5) months after the first sample at second-line failure. Median HIV-1 RNA was unchanged from the first sample at 4.5 log₁₀ copies/ml [IQR 3.5–5.0 log₁₀ copies/ml]. The genotypic resistance profile was also unchanged. Mean genotypic susceptibility score was 2.9 (±0.4) at second-line failure; this was unchanged for those with a repeat sample.

In patients aged 15–35 years, 29% had drug-resistant virus, compared with 42% of those aged >35 years, although this difference did not reach statistical significance. Thirty-one percent of individuals failing treatment with HIV RNA>10,000 copies/ml had drug-resistant virus, compared with 43% of individuals with HIV RNA≤10,000 copies/ml (p

0.66).

Discussion

In this large ART roll-out program in South Africa we identified patients with confirmed virologic failure on second-line ART. Despite the absence of major PI resistance at first-line ART failure, most individuals failed second-line ART quickly (e.g. within a mean of 10 months) and two-thirds failed with wild-type virus. Furthermore, while patients remained on second-line ART with continued virologic failure, drug resistance did not develop over the follow-up period.

Given the known potency of second-line ART regimens and the low frequency of drug resistant virus found, it appears that medication non-adherence is an important cause of second-line ART failure. While access to pharmacy refill, pill count, and patient-level pharmacokinetic data were not available, there are plausible patient-level, regimen-specific, and structural explanations for adherence problems on second-line ART. Drug toxicities related to lopinavir and didanosine and the buffered formulation of didanosine (the enteric-coated formulation was unavailable at the study site) likely hindered adherence [18], [19]. Social and structural obstacles to adherence can include inaccessible clinic location or lack of access to transportation, work/child-care responsibilities, and decreased health care provider to patient ratio as a consequence of the rapid growth in ART roll-out programs [20], [21], [22]. ART shortages, though not problematic at this site, can also be a challenge.

Most patients had substitutions in PR at sites that are known to be polymorphic in HIV-1 subtype C. These minor resistance mutations were also present at first-line ART failure in samples from the 10 patients who had samples available for sequencing from that time point. This observation confirms a prior genotype study from this clinic of HIV-infected individuals who were ART-naïve and who had failed first-line where the same polymorphisms in PR were present [4]. It is also consistent with other studies that performed genotypic analysis of individuals infected with HIV-1 subtype C who were ART-naïve [23], [24], [25], [26]. The impact of these polymorphisms has been debated, without clear clinical evidence that they affect drug susceptibility [27], [28].

Despite the absence of NNRTI exposure on second-line ART, virus from almost 30% of patients had at least one major NNRTI resistance mutation and virus from 15% had a mutation at the K103N codon, which suggests ongoing resistance to nevirapine and efavirenz. The persistence of NNRTI resistance is consistent with genotypic analysis of two other public sector South African cohorts of patients that failed PI-based ART [29], [30]. The low frequency of etravirine-associated mutations suggests excellent susceptibility to this next-generation NNRTI if it were to become available.

There are several therapeutic implications for the absence of NRTI resistance at second-line failure in this study. While other studies have suggested a higher rate of emergence of K65R at the time of stavudine-based ART failure in HIV-1 subtype C infection, we found that K65R did not appear after exposure to first-line stavudine or second-line didanosine; this may hold promise for the increasing use of tenofovir in resource-limited settings with predominance of nonsubtype-B HIV clades [31], [32]. M184V mutation and TAMs became undetectable supporting the hypothesis that lack of drug exposure due to ART non-adherence was the most likely cause of ART failure. In addition, consideration of archived resistance mutations is important in selection of second-line ART [33].

Females represented 85% of the patients whose viruses were sequenced, which is slightly higher than the distribution of females commencing second-line ART (75%)[9]. While the demographic and clinical characteristics of the cohort are largely consistent with other large ART programs, the small sample size may limit generalizability [34], [35]. Limited data were available on ART adherence, pharmacokinetic data, and contextual co-variates that may have an important impact on ART use and effectiveness. For example, those who receive treatment for other conditions, such as tuberculosis, may experience decreased levels of lopinavir/ritonavir if they are concomitantly taking rifampicin [36]. Because data on prior ART exposure, such as for prevention of mother-to-child transmission were not available, we limited the analysis to individuals who were documented as ART naïve at initiation of first-line ART in the clinical record. This study did not test for minority drug-resistance variants that are not detected by conventional genotypic testing but contribute to ART failure [37].

The low frequency of drug resistance to boosted-lopinavir at the time of virologic failure in this large ART-roll out program in Cape Town confirms other studies in Johannesburg and Soweto, South Africa, as well as in North America and Europe [29], [30], [38], [39]. In vivo resistance data suggest that the accumulation of accessory mutations in PR occurs rapidly only after major protease resistance mutations are established [40]. The absence of new PR mutations over a short interval of virologic failure on PI-based second-line ART is consistent with this observation.

In those who experience virologic failure on second-line ART in South Africa, ART failure occurs quickly and most often with wild-type virus. However, rapid development of resistance does not occur. Interventions that successfully improve adherence could allow patients to continue to benefit from second-line ART therapy even after initial failure.

Acknowledgments

The authors gratefully acknowledge the dedicated staff of the Hannan Crusaid ART clinic and the Desmond Tutu HIV Centre and Toga Laboratories for assistance with storage and retrieval of specimens.

Footnotes

Competing Interests: The authors have read the journal's policy and have the following competing interest: DRK is a consultant to and has received honoraria or research support from Abbott, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck and ViiV. This does not alter the authors' adherence to all the PloS ONE policies on sharing data and materials. All other authors have declared that no competing interests exist.

Funding: This project was supported by the United States National Institute of Allergy and Infectious Diseases (NIAID T32 AI007433, R01AI058736, K24 A1062476), the National Center for Research Resources (K24 RR016482), Harvard University Center for AIDS Research (P30-AI060354), Virology Specialty Laboratory subcontract from the AIDS Clinical Trials Group (U01 AI068636). SG was a recipient of the “Agence Nationale de Recherche sur le SIDA” (French National Agency for Research on AIDS) Fellowship Grant for Post-Graduate Studies, France. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. UNAIDS Joint United Nations Programme on HIV/AIDS. Country Fact Sheets: South Africa. 2010. Available: http://cfs.unaids.org/factsheet.htm?lng_code=en. Accessed: 2011 June 14.

2. Long L, Fox M, Sanne I, Rosen S. The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa. AIDS. 2010;24:915–919. [PubMed]

3. World Health Organization. Prioritizing Second-Line Antiretroviral Drugs for Adults and Adolescents: A Public Health Approach. Geneva: World Health Organization, HIV Department; 2007. Available: http://www.who.int/hiv/pub/meetingreports/Second_Line_Antiretroviral.pdf. Accessed: 2012 February 8.

4. Orrell C, Walensky RP, Losina E, Pitt J, Freedberg KA, et al. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther. 2009;14:523–531. [PMC free article] [PubMed]

5. Walmsley S, Bernstein B, King M, Arribas J, Beall G, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039–2046. [PubMed]

6. Murphy RA, Sunpath H, Lu Z, Chelin N, Losina E, et al. Outcomes after virologic failure of first-line ART in South Africa. AIDS. 2010;24:1007–1012. [PMC free article] [PubMed]

7. Hosseinipour MC, Kumwenda JJ, Weigel R, Brown LB, Mzinganjira D, et al. Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med. 2010;11:510–518. [PubMed]

8. Fox MP, Ive P, Long L, Maskew M, Sanne I. High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2009;53:500–506. [PubMed]

9. Levison JH, Orrell C, Losina E, Lu Z, Freedberg KA, et al. Early outcomes and the virological effect of delayed treatment switching to second-line therapy in an antiretroviral roll-out programme in South Africa. Antivir Ther. 2011;16:853–861. [PMC free article] [PubMed]

10. Marconi VC, Sunpath H, Lu Z, Gordon M, Koranteng-Apeagyei K, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis. 2008;46:1589–1597. [PMC free article] [PubMed]

11. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global trends in molecular epidemiology of HIV-1 during 2000–2007. AIDS. 2011;25:679–689. [PubMed]

12. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS. 2005;19:2141–2148. [PubMed]

13. Orrell C, Harling G, Lawn SD, Kaplan R, McNally M, et al. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther. 2007;12:83–88. [PubMed]

14. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS. 2004;18:887–895. [PubMed]

15. National Department of Health South Africa. Clinical Guidelines for the Management of HIV and AIDS in Adults and Adolescents, 2010. Available: http://www.fidssa.co.za/Guidelines/2010_Adult_ART_Guidelines.pdf. Accessed: 2012 February 8.

16. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med. 2010;18:156–163. [PubMed]

17. Wallis CL, Papathanasopoulos MA, Lakhi S, Karita E, Kamali A, et al. Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. J Virol Methods. 2010;163:505–508. [PMC free article] [PubMed]

18. Kunches LM, Reinhalter NE, Marquis A, Coakley E, Cohen C, et al. Tolerability of enteric-coated didanosine capsules compared with didanosine tablets in adults with HIV infection. J Acquir Immune Defic Syndr. 2001;28:150–153. [PubMed]

19. Barreiro P, Corbaton A, Nunez M, Gonzalez-Lahoz J, Soriano V. Tolerance of didanosine as enteric-coated capsules versus buffered tablets. AIDS Patient Care STDS. 2004;18:329–331. [PubMed]

20. Miller CM, Ketlhapile M, Rybasack-Smith H, Rosen S. Why are antiretroviral treatment patients lost to follow-up? A qualitative study from South Africa. Trop Med Int Health. 2010;15(Suppl 1):48–54. [PMC free article] [PubMed]

21. Pasquet A, Messou E, Gabillard D, Minga A, Depoulosky A, et al. Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Cote d'Ivoire. PLoS One. 2010;5:e13414. [PMC free article] [PubMed]

22. Geng EH, Bangsberg DR, Musinguzi N, Emenyonu N, Bwana MB, et al. Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr. 2010;53:405–411. [PMC free article] [PubMed]

23. Bellocchi MC, Forbici F, Palombi L, Gori C, Coelho E, et al. Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM programme. J Med Virol. 2005;76:452–458. [PubMed]

24. Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Liegeois F, et al. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol. 2000;38:3919–3925. [PMC free article] [PubMed]

25. Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2005;2:e112. [PMC free article] [PubMed]

26. Grossman Z, Vardinon N, Chemtob D, Alkan ML, Bentwich Z, et al. Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B. AIDS. 2001;15:1453–1460. [PubMed]

27. Frater AJ, Beardall A, Ariyoshi K, Churchill D, Galpin S, et al. Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients. AIDS. 2001;15:1493–1502. [PubMed]

28. Velazquez-Campoy A, Todd MJ, Vega S, Freire E. Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes. Proc Natl Acad Sci U S A. 2001;98:6062–6067. [PubMed]

29. Wallis CL, Mellors JW, Venter WDF, Sanne I, Stevens W. Protease inhibitor resistance is uncommon in HIV-1 subtype C infected patients on failing second-line lopinavir/r-containing antiretroviral therapy in South Africa. AIDS Research and Treatment. 2011;2011:769627. [PMC free article] [PubMed]

30. El-Khatib Z, Ekstrom AM, Ledwaba J, Mohapi L, Laher F, et al. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS. 2010;24:1679–1687. [PMC free article] [PubMed]

31. World Health Organization. Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector. 2010. Available: http://www.who.int/hiv/pub/towards_universal_access_report_2008.pdf. Accessed: 2012 February 8.

32. Li JF, Lipscomb JT, Wei X, Martinson NA, Morris L, et al. Detection of low-level K65R variants in nucleoside reverse transcriptase inhibitor-naive chronic and acute HIV-1 subtype C infections. J Infect Dis. 2011;203:798–802. [PMC free article] [PubMed]

33. Ross LL, Rouse E, Gerondelis P, DeJesus E, Cohen C, et al. Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir. J Antimicrob Chemother. 2010;65:307–315. [PMC free article] [PubMed]

34. Bekker LG, Myer L, Orrell C, Lawn S, Wood R. Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Gugulethu, South Africa. S Afr Med J. 2006;96:315–320. [PubMed]

35. Nash D, Katyal M, Brinkhof MW, Keiser O, May M, et al. Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS. 2008;22:2291–2302. [PMC free article] [PubMed]

36. Decloedt EH, McIlleron H, Smith P, Merry C, Orrell C, et al. Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets. Antimicrob Agents Chemother. 2011;55:3195–3200. [PMC free article] [PubMed]

37. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA. 2011;305:1327–1335. [PMC free article] [PubMed]

38. Gupta R, Hill A, Sawyer AW, Pillay D. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis. 2008;47:712–722. [PubMed]

39. Walmsley S, Loutfy M. Can structured treatment interruptions (STIs) be used as a strategy to decrease total drug requirements and toxicity in HIV infection? J Int Assoc Physicians AIDS Care (Chic Ill) 2002;1:95–103. [PubMed]

40. Mo H, King MS, King K, Molla A, Brun S, et al. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates. J Virol. 2005;79:3329–3338. [PMC free article] [PubMed]

Articles from PLoS ONE are provided here courtesy of
Public Library of Science